AUS
NZ
UK
CA
USA
IND
Starpharma Holdings (ASX:SPL) has lodged a patent application for its proprietary DEP® dendrimer technology applied to radioligand therapy, after preclinical studies demonstrated enhanced biodistribution, increased tumour uptake, and decreased off-target accumulation across multiple cancer targets. The Melbourne-based biotech firm reported consistent data across HER2, PSMA, and EGFR-targeted constructs, reinforcing DEP® as a versatile and modular radiopharmaceutical platform. This advancement coincides with the global radiopharmaceutical market, currently valued near US$8 billion, projected to grow to approximately US$15 billion by 2030, positioning the sector as one of the fastest expanding fields in precision oncology. Starpharma management has identified partnering as a critical strategic focus for the DEP® radiopharmaceutical program, attracting investor attention.<\/p> <\/div>
Key Points<\/h3>
- Company: Starpharma Holdings Limited (ASX: SPL, US OTC: SPHRY)<\/li>
- New patent application filed for DEP® dendrimer technology in radioligand therapy (RLT)<\/li>
- Preclinical results reveal improved biodistribution with enhanced tumour uptake and retention, alongside reduced off-target accumulation across HER2, PSMA, and EGFR targets<\/li>
- Global radiopharmaceutical market valued at about US$8 billion, expected to reach US$15 billion by 2030<\/li>
- Starpharma actively exploring partnerships with specialist radiopharmaceutical and oncology companies<\/li>
- Investors should monitor partnering announcements and updates on preclinical or clinical progress in the DEP® radiopharmaceutical pipeline<\/li>
<\/ul>
<\/div>
Starpharma Files Patent to Secure DEP® Dendrimer Application in Radioligand Therapy<\/h2>
On 2 July 2026, Starpharma announced the submission of a new patent application specifically protecting the use of its DEP® dendrimer technology in radioligand therapy. This filing aims to safeguard the company’s radiopharmaceutical drug delivery approach across various oncology targets, strengthening Starpharma’s capacity to develop and commercialise a portfolio of differentiated Assets<\/a> within this field.<\/p>
The company noted the patent is intended to cover DEP® radiopharmaceutical methods across multiple targets rather than a single compound or indication, highlighting the platform’s broad applicability. This extensive coverage is strategically important as it may provide Starpharma with the intellectual property framework to pursue simultaneous partnering programs across diverse tumour types and targeting strategies. The filing follows encouraging and consistent preclinical data across several oncology targets.<\/p>
Preclinical Data Show Enhanced Biodistribution Across HER2, PSMA, and EGFR Targets<\/h2>
The patent application is supported by preclinical studies conducted on targeted dendrimer radiopharmaceutical constructs against three established oncology targets: HER2, PSMA, and EGFR. Starpharma reported robust and sustained tumour uptake with prolonged tumour-associated signal post-dosing. Additionally, low off-target accumulation was observed, including reduced kidney and systemic exposure, coupled with rapid blood clearance and efficient renal excretion without extended kidney retention.<\/p>
The reproducibility of this biodistribution profile across multiple targets suggests the DEP® platform’s effects arise from its dendrimer technology rather than isolated construct results. Starpharma indicated these findings imply DEP® may facilitate delivery of therapeutically relevant radiation doses to tumours while limiting exposure to healthy tissues, potentially offering an improved therapeutic window compared to current radiopharmaceutical methods. It is important to note these are preclinical results and have not yet undergone evaluation in human Clinical Trials<\/a>.<\/p>
DEP® Dendrimer Technology Designed to Address Radioligand Therapy Challenges<\/h2>
Effective tumour targeting with minimal off-target toxicity remains a major challenge in radioligand therapy. Existing modalities, including peptides, antibody fragments, and full antibodies, face trade-offs between tumour delivery efficiency, kidney exposure, and systemic circulation duration. Peptides and fragments often exhibit high kidney uptake, while antibodies can cause prolonged systemic exposure, both limiting therapeutic windows and increasing healthy organ toxicity risks.<\/p>
Starpharma’s DEP® dendrimer technology is engineered to overcome these challenges via controlled delivery and optimized biodistribution. The dendrimer—a precisely synthesized nanoscale molecule with extensive branching, polyvalency, and water solubility—is designed to offer tuneable pharmacokinetics. This enables developers to adjust radiopharmaceutical delivery characteristics in a controlled way, potentially yielding differentiated performance versus conventional approaches. The company has over 20 years of experience applying dendrimer technology across diverse medical and pharmaceutical applications.<\/p>
CEO Cheryl Maley Highlights DEP® Platform’s Potential in Radiopharmaceuticals<\/h2>
Starpharma CEO Cheryl Maley commented on the preclinical data and patent filing, emphasizing the DEP® platform’s potential to provide a distinctive radiopharmaceutical profile combining strong tumour targeting with reduced off-target exposure. She described radiopharmaceuticals as a dynamic and rapidly expanding oncology area and expressed confidence that DEP® is well positioned to address key limitations of existing therapies.<\/p>
Maley linked the patent filing to the company’s broader commercialisation strategy, stating that reinforcing the platform’s intellectual property supports value creation through developing and partnering multiple DEP® radiopharmaceutical programs. The reference to multiple programs aligns with the platform’s applicability across HER2, PSMA, and EGFR targets, indicating Starpharma’s ambitions extend beyond a single asset or partnership. No specific timelines or financial details regarding current or future partnerships were disclosed.<\/p>
Radiopharmaceutical Market Valued at US$8 Billion with Strong Growth Attracting Major Pharma<\/h2>
The global radiopharmaceutical market is currently estimated at approximately US$8 billion and is forecasted to grow to about US$15 billion by 2030, according to Starpharma’s update. This growth is driven by positive clinical outcomes from approved radioligand therapies for prostate cancer, neuroendocrine tumours, and others, which have spurred significant investor and partnership interest in recent years.<\/p>
Major pharmaceutical companies have shown strong strategic interest, including acquisitions and licensing deals involving radiopharmaceutical platforms and assets. This external market environment is directly relevant to Starpharma’s partnering strategy. The company positions DEP® as a platform technology that can enhance existing radiopharmaceutical approaches, potentially making it attractive to larger firms seeking differentiated delivery solutions for their radioligand pipelines. Starpharma continues to explore partnerships with specialist radiopharmaceutical and oncology companies to Leverage<\/a> its DEP® technology in this evolving sector.<\/p>
Modular Platform Enables Multiple Parallel Partnering Opportunities Across Oncology Targets<\/h2>
A strategically important aspect of the DEP® radiopharmaceutical data is the platform’s modular design. Consistent biodistribution results across HER2, PSMA, and EGFR—three distinct, commercially significant oncology targets—indicate DEP® technology can be broadly applied across tumour types without requiring fundamentally different engineering per target.<\/p>
This modularity allows for potential parallel partnering programs, enabling Starpharma to pursue separate licensing or collaboration agreements for different targets simultaneously rather than sequentially. Management noted this platform approach could facilitate development of multiple differentiated radiopharmaceutical assets. While no partnering deals have been announced, the combination of consistent preclinical data and a new patent application strengthens Starpharma’s position in negotiations with prospective partners.<\/p>
Context Within Starpharma’s Broader DEP® Portfolio and Pipeline<\/h2>
The radiopharmaceutical program is part of a wider Starpharma portfolio that includes three clinical-stage DEP® assets, additional preclinical radiopharmaceutical candidates, multiple research collaborations, and three commercially marketed over-the-counter products. With over 20 years of dendrimer platform development across therapeutic areas, the radiopharmaceutical program represents a newer but increasingly significant focus.<\/p>
The DEP® platform’s core value proposition—enhancing delivery and pharmacokinetics of existing drug classes via dendrimer-based formulation—is consistent across oncology and non-oncology programs. Extending this approach to radioligand therapy is a logical step, given similar delivery challenges between radiopharmaceuticals and conventional oncology drugs. Investors tracking Starpharma’s pipeline will recognize the radiopharmaceutical program and patent filing as additional potential growth drivers alongside existing clinical-stage assets.<\/p>
Intellectual Property Strategy and Implications of the New Patent Application<\/h2>
Filing a patent application specifically for DEP® dendrimer use in radioligand therapy marks a deliberate move in Starpharma’s IP strategy. Patent protection in radiopharmaceuticals is commercially critical, as it helps maintain control over a technology platform when pursuing partnerships or licensing with larger industry players. Without strong IP, platform technologies risk being replicated or circumvented by competitors.<\/p>
Starpharma’s update emphasized that the application is expected to protect multiple targets rather than a single construct, potentially providing a broader defensive IP perimeter. It is important to note that a patent application does not guarantee granted protection, as it remains subject to examination by patent authorities. The company did not disclose filing jurisdictions or timelines for examination or grant. Investors should monitor updates on the application’s progress.<\/p>
Investor Considerations as Starpharma Advances DEP® Radiopharmaceutical Program<\/h2>
Investors should closely watch Starpharma’s progress in partnering discussions within the radiopharmaceutical sector. The company has highlighted that consistent cross-target data and the new patent filing enhance its position to pursue such opportunities, indicating ongoing engagement with potential partners. Any formal partnership announcement—whether licensing, research collaboration, or commercial deal—would be a major milestone.<\/p>
Additionally, investors will look for further preclinical radiopharmaceutical data, including indications of advancement toward clinical evaluation in humans. Current radiopharmaceutical assets remain preclinical, implying a significant development timeline before clinical data emerge. The patent application’s progression will also be a relevant medium-term indicator. The immediate impact of this announcement on Starpharma’s share price was unclear at the time of publication.<\/p>
Starpharma Files Patent to Secure DEP® Dendrimer Application in Radioligand Therapy<\/h2>
On 2 July 2026, Starpharma announced the submission of a new patent application specifically protecting the use of its DEP® dendrimer technology in radioligand therapy. This filing aims to safeguard the company’s radiopharmaceutical drug delivery approach across various oncology targets, strengthening Starpharma’s capacity to develop and commercialise a portfolio of differentiated Assets<\/a> within this field.<\/p>
The company noted the patent is intended to cover DEP® radiopharmaceutical methods across multiple targets rather than a single compound or indication, highlighting the platform’s broad applicability. This extensive coverage is strategically important as it may provide Starpharma with the intellectual property framework to pursue simultaneous partnering programs across diverse tumour types and targeting strategies. The filing follows encouraging and consistent preclinical data across several oncology targets.<\/p>
The patent application is supported by preclinical studies conducted on targeted dendrimer radiopharmaceutical constructs against three established oncology targets: HER2, PSMA, and EGFR. Starpharma reported robust and sustained tumour uptake with prolonged tumour-associated signal post-dosing. Additionally, low off-target accumulation was observed, including reduced kidney and systemic exposure, coupled with rapid blood clearance and efficient renal excretion without extended kidney retention.<\/p>
The reproducibility of this biodistribution profile across multiple targets suggests the DEP® platform’s effects arise from its dendrimer technology rather than isolated construct results. Starpharma indicated these findings imply DEP® may facilitate delivery of therapeutically relevant radiation doses to tumours while limiting exposure to healthy tissues, potentially offering an improved therapeutic window compared to current radiopharmaceutical methods. It is important to note these are preclinical results and have not yet undergone evaluation in human Clinical Trials<\/a>.<\/p>
Effective tumour targeting with minimal off-target toxicity remains a major challenge in radioligand therapy. Existing modalities, including peptides, antibody fragments, and full antibodies, face trade-offs between tumour delivery efficiency, kidney exposure, and systemic circulation duration. Peptides and fragments often exhibit high kidney uptake, while antibodies can cause prolonged systemic exposure, both limiting therapeutic windows and increasing healthy organ toxicity risks.<\/p>
Starpharma’s DEP® dendrimer technology is engineered to overcome these challenges via controlled delivery and optimized biodistribution. The dendrimer—a precisely synthesized nanoscale molecule with extensive branching, polyvalency, and water solubility—is designed to offer tuneable pharmacokinetics. This enables developers to adjust radiopharmaceutical delivery characteristics in a controlled way, potentially yielding differentiated performance versus conventional approaches. The company has over 20 years of experience applying dendrimer technology across diverse medical and pharmaceutical applications.<\/p>
Starpharma CEO Cheryl Maley commented on the preclinical data and patent filing, emphasizing the DEP® platform’s potential to provide a distinctive radiopharmaceutical profile combining strong tumour targeting with reduced off-target exposure. She described radiopharmaceuticals as a dynamic and rapidly expanding oncology area and expressed confidence that DEP® is well positioned to address key limitations of existing therapies.<\/p>
Maley linked the patent filing to the company’s broader commercialisation strategy, stating that reinforcing the platform’s intellectual property supports value creation through developing and partnering multiple DEP® radiopharmaceutical programs. The reference to multiple programs aligns with the platform’s applicability across HER2, PSMA, and EGFR targets, indicating Starpharma’s ambitions extend beyond a single asset or partnership. No specific timelines or financial details regarding current or future partnerships were disclosed.<\/p>
The global radiopharmaceutical market is currently estimated at approximately US$8 billion and is forecasted to grow to about US$15 billion by 2030, according to Starpharma’s update. This growth is driven by positive clinical outcomes from approved radioligand therapies for prostate cancer, neuroendocrine tumours, and others, which have spurred significant investor and partnership interest in recent years.<\/p>
Major pharmaceutical companies have shown strong strategic interest, including acquisitions and licensing deals involving radiopharmaceutical platforms and assets. This external market environment is directly relevant to Starpharma’s partnering strategy. The company positions DEP® as a platform technology that can enhance existing radiopharmaceutical approaches, potentially making it attractive to larger firms seeking differentiated delivery solutions for their radioligand pipelines. Starpharma continues to explore partnerships with specialist radiopharmaceutical and oncology companies to Leverage<\/a> its DEP® technology in this evolving sector.<\/p>
A strategically important aspect of the DEP® radiopharmaceutical data is the platform’s modular design. Consistent biodistribution results across HER2, PSMA, and EGFR—three distinct, commercially significant oncology targets—indicate DEP® technology can be broadly applied across tumour types without requiring fundamentally different engineering per target.<\/p>
This modularity allows for potential parallel partnering programs, enabling Starpharma to pursue separate licensing or collaboration agreements for different targets simultaneously rather than sequentially. Management noted this platform approach could facilitate development of multiple differentiated radiopharmaceutical assets. While no partnering deals have been announced, the combination of consistent preclinical data and a new patent application strengthens Starpharma’s position in negotiations with prospective partners.<\/p>
The radiopharmaceutical program is part of a wider Starpharma portfolio that includes three clinical-stage DEP® assets, additional preclinical radiopharmaceutical candidates, multiple research collaborations, and three commercially marketed over-the-counter products. With over 20 years of dendrimer platform development across therapeutic areas, the radiopharmaceutical program represents a newer but increasingly significant focus.<\/p>
The DEP® platform’s core value proposition—enhancing delivery and pharmacokinetics of existing drug classes via dendrimer-based formulation—is consistent across oncology and non-oncology programs. Extending this approach to radioligand therapy is a logical step, given similar delivery challenges between radiopharmaceuticals and conventional oncology drugs. Investors tracking Starpharma’s pipeline will recognize the radiopharmaceutical program and patent filing as additional potential growth drivers alongside existing clinical-stage assets.<\/p>
Filing a patent application specifically for DEP® dendrimer use in radioligand therapy marks a deliberate move in Starpharma’s IP strategy. Patent protection in radiopharmaceuticals is commercially critical, as it helps maintain control over a technology platform when pursuing partnerships or licensing with larger industry players. Without strong IP, platform technologies risk being replicated or circumvented by competitors.<\/p>
Starpharma’s update emphasized that the application is expected to protect multiple targets rather than a single construct, potentially providing a broader defensive IP perimeter. It is important to note that a patent application does not guarantee granted protection, as it remains subject to examination by patent authorities. The company did not disclose filing jurisdictions or timelines for examination or grant. Investors should monitor updates on the application’s progress.<\/p>
Investors should closely watch Starpharma’s progress in partnering discussions within the radiopharmaceutical sector. The company has highlighted that consistent cross-target data and the new patent filing enhance its position to pursue such opportunities, indicating ongoing engagement with potential partners. Any formal partnership announcement—whether licensing, research collaboration, or commercial deal—would be a major milestone.<\/p>
Additionally, investors will look for further preclinical radiopharmaceutical data, including indications of advancement toward clinical evaluation in humans. Current radiopharmaceutical assets remain preclinical, implying a significant development timeline before clinical data emerge. The patent application’s progression will also be a relevant medium-term indicator. The immediate impact of this announcement on Starpharma’s share price was unclear at the time of publication.<\/p>
Preclinical Data Show Enhanced Biodistribution Across HER2, PSMA, and EGFR Targets<\/h2>
DEP® Dendrimer Technology Designed to Address Radioligand Therapy Challenges<\/h2>
CEO Cheryl Maley Highlights DEP® Platform’s Potential in Radiopharmaceuticals<\/h2>
Radiopharmaceutical Market Valued at US$8 Billion with Strong Growth Attracting Major Pharma<\/h2>
Modular Platform Enables Multiple Parallel Partnering Opportunities Across Oncology Targets<\/h2>
Context Within Starpharma’s Broader DEP® Portfolio and Pipeline<\/h2>
Intellectual Property Strategy and Implications of the New Patent Application<\/h2>
Investor Considerations as Starpharma Advances DEP® Radiopharmaceutical Program<\/h2>
